Customization of MIT Mouse Recombinant mAb
Preparing humanized antibodies on the basis of mouse-derived antibodies is one of the mainstream antibody drug technologies. We provide Magnetic & Immunization & Tandem (MIT) mouse monoclonal antibody customization service to address problems appeared from conventional mouse-derived antibody (hybridoma monoclonal antibody) preparation technologies, such as long preparation period, heavy screening workload, and small amount of candidate antibodies.
1. Clear Antibody Sequence Reducing Redundant Screening
Genetic engineering and phage display technology are used to obtain the gene sequence of the antibody directly, reducing unnecessary screening.
2. Three Months Faster than Hybridoma to Speed up Drug R&D
This service takes only 2 months for library construction and screening, which is nearly 3 months faster than the screening process of hybridoma technology and can speed up the R&D progress significantly.
3. Delivery of Dozens to Hundreds of High-Affinity Lead Antibody Molecules
Dozens to hundreds of candidate molecules can be obtained for each target using an arrayed multi-library approach and a multi-species library screening strategy. In this way, the candidate antibodies have higher affinity at pM level typically.
4. Immunization through Multiple Sites\Species to Increase Species Cross-activity of Candidate Antibodies
With up to 4 mouse strains, multiple immunization approaches, species of immunogens, and screening methods, it’s easier to increase species cross-activity of antibody molecules.
5. Ensure Drug Developability through Eukaryotic Expression System and Cellular Level Verification
The candidate molecules are expressed through eukaryotic system and followed by physicochemical characteristics and cellular function testing to ensure the delivered lead antibody has good drug developability.
SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.Learn more
After the base is put into operation, SMOC’s capability to provide genetically modified rat/mouse models and technical services including gene function research and drug development will be greatly enhanced.Learn more